Current guidelines recommend a duration of 24 weeks of treatment with pegylated interferon and ribavirin for patients infected with chronic hepatitis C virus (HCV) genotypes 2 and 3. Several trials investigated whether shorter treatment duration is equally effective in achieving sustained virological response (SVR). Our aim was to determine the optimal length of treatment in patients with HCV genotypes 2 and 3.
Methods
Systematic literature identified eight randomized controlled trials (RCTs). Meta-analyses were carried out on SVR data from three studies randomized at baseline and five studies randomized at rapid virological response (RVR) to either 12–16 weeks or a 24-week course.
Results
Pooled SVR data were higher in standard treatment in RCTs that randomized at baseline, with a relative risk (RR) of 0.88 (95% confidence interval [CI] 0.76–1.01). The pooled proportion of SVR rates of RCTs that randomized at RVR were similar in the short treatment group (82%) as in the standard treatment (83%), with the pooled effect given by a RR of 1.00 (95% CI 0.92–1.09).
Conclusions
A shorter course (12–16 weeks) of combination therapy does not impair efficacy compared with a 24-week course in HCV genotypes 2 and 3 patients who achieve an RVR. HCV patients without RVR should consider 24 weeks of treatment.
References
1.
LauerG.M., WalkerB.D.Hepatitis C infection.N Engl J Med2001; 345: 41–52.
2.
GhanyM.G., StraderD.B., ThomasD.L.Diagnosis, management, and treatment of hepatitis C: an update.Hepatology2009; 49: 1335–1374.
3.
De BruijneJ., BusterE.H., GelderblomH.C.Treatment of chronic hepatitis C virus infection – Dutch national guidelines.Neth J Med2008; 66: 311–322.
4.
HadziyannisS.J., SetteH.Jr., MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med2004; 140: 346–355.
5.
FontangesT., BeorchiaS., DouvinC.Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection.Gastroenterol Clin Biol2007; 31: 566–572.
6.
ShiffmanMl, SuterF., BaconB.R.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.N Engl J Med2007; 357: 124–134.
7.
ZekryA., PatelK., MuirA.Tinkering and tailoring with HCV therapy: can we get away with less?Hepatology2004; 40: 1249–1251.
8.
MangiaA., SantoroR., MinervaN.Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.N Engl J Med2005; 352: 2609–2617.
9.
laggingM., langelandN., PedersenC.Randomised comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.Hepatology2008; 47: 1837–1845.
10.
DalgardO., BjøroK., Ring-larsenH.Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.Hepatology2008; 47: 35–42.
11.
von WagnerM., HuberM., BergT.Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.Gastroenterology2005; 129: 522–527.
12.
AndriulliA., MangiaA., IacobellisA.Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.Aliment Pharmacol Ther2008; 28: 397–404.
13.
AndriulliA., DalgardO., BjøroK.Short-term treatment duration for HCV-2 and HCV-3 infected patients.Dig Liver Dis2006; 38: 741–748.
14.
DalgardO., BjøroK., HellumK.B.Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.Hepatology2004; 40: 1260–1265.
15.
MoherD., CookD.J., EastwoodS., OlkinI., RennieD., StroupD.F.Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.Lancet1999; 354: 1896–1900.
16.
JadadA.R., MooreR.A., CarrollD.Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials1996; 17: 1–12.
17.
YuMl, DaiC.Y., HuangJ.F.A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.Gut2007; 56: 553–559.
18.
FarooqiJ.I., FarooqiR.J.Conventional interferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.Asian Pacific Digestive Week. 15–18 October 2007, Kobe, Japan. Abstract 218.
19.
MecenateF., BarbaroG., PellicelliA.Comparison of peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the Cleo Trial.58th Annual Meeting of the American Association for the Study of Liver Diseases. 2–6 November 2007, Boston, MA, USA. Abstract 1327.
20.
BonardiR., MancaA., TaboneM.The efficacy of a 12 weeks course of pegylated interferon alpha-2b (Peg-IFN) and ribavirin (RBV) is similar to a standard 24 weeks course, regardless of basal viremic level.9th Annual Meeting of the European Society for Clinical Virology. 3–6 September 2006, Birmingham, UK. Abstract 246.
21.
ReddyK.R., HoofnagleJ.H., TongM.J.Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.Hepatology1999; 30: 787–793.
22.
MuirA.J., BornsteinJ.D., KillenbergP.G., the Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.N Engl J Med2004; 350: 2265–2271.
23.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
24.
ShiffmanMl, WilsonM., SalvatoriJ.Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and epoetin alfa (EPO) enhances sustained virologic response (SVR).Hepatology2005; 42: 217.
25.
McHutchisonJ., SulkowskiM.Scientific rationale and study design of the individualized dosing efficacy vs fat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.J Viral Hepat2008; 15: 475–481.
26.
ToyodaH., KumadaT., KiriyamaS.Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.Liver Int2009; 29: 120–125.
